A

n international tribunal sided against Eli Lilly in a closely watched claim that the drug maker brought against the Canadian government over its right to set patent laws.

The dispute centered on different Canadian court rulings several years ago that invalidated patents on two Lilly drugs. Those decisions prompted the arrival of cheaper generics on the Canadian market, which Lilly claims led to “significant” sales and job losses in Canada.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories